Diamond Member Pelican Press 0 Posted June 21, 2024 Diamond Member Share Posted June 21, 2024 Zealand Pharma’s ***** reduces weight by 8.6% in early-stage study, ET HealthWorld London: Zealand Pharma said on Thursday an early-stage study showed a high dose of its ***** helped reduce weight by an average 8.6 per cent after 16 weekly doses. The company said the data paves the way for testing the *****, petrelintide, in a mid-stage trial for weight loss, which it expects to start later this year. The weight loss achieved with the high dose of the ***** was much higher than the 1.7 per cent reduction with a placebo in one part of the trial that involved 48 participants. Another part of the early-stage study was testing the ***** in 20 people with lower doses. Petrelintide belongs to a class of drugs known as the long-acting amylin analog, which mimics a hormone called amylin that is co-secreted with insulin in response to ingested nutrients. The Danish company is also working with ******* drugmaker Boehringer Ingelheim to test another ***** survodutide, which belongs to the same class of GLP-1 agonists as Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar) Published On Jun 21, 2024 at 05:56 AM IST This is the hidden content, please Sign In or Sign Up weight loss *****, Health News, Zealand Pharma, *****, petrelintide, early-stage study, high dose, reduce weight #Zealand #Pharmas #***** #reduces #weight #earlystage #study #HealthWorld This is the hidden content, please Sign In or Sign Up 0 Quote Link to comment https://hopzone.eu/forums/topic/49444-zealand-pharma%E2%80%99s-drug-reduces-weight-by-86-in-early-stage-study-et-healthworld/ Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.